Association between spironolactone added to beta-blockers and ACE inhibition and survival in heart failure patients with reduced ejection fraction: a propensity score-matched cohort study
Authors:
- 7 June 2013
- journal article
- clinical trial
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 69 (10) , 1747-1755
Abstract
Heart failure (CHF) guidelines recommend mineralocorticoid receptor antagonists for all symptomatic patients treated with a combination of ACE inhibitors/angiotensin receptor blockers (ARBs) and beta-blockers. As opposed to both eplerenone trials, patients in RALES (spironolactone) received almost no beta-blockers. Since pharmacological properties differ between eplerenone and spironolactone, the prognostic benefit of spironolactone added to this baseline combination therapy needs clarification.Keywords
This publication has 27 references indexed in Scilit:
- ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESCEuropean Heart Journal, 2012
- Incremental Reduction in Risk of Death Associated With Use of Guideline‐Recommended Therapies in Patients With Heart Failure: A Nested Case‐Control Analysis of IMPROVE HFJournal of the American Heart Association, 2012
- Eplerenone in Patients with Systolic Heart Failure and Mild SymptomsNew England Journal of Medicine, 2011
- 2009 Focused Update Incorporated Into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in AdultsCirculation, 2009
- Aldosterone blockade in patients with heart failure and a reduced left ventricular ejection fractionEuropean Heart Journal, 2008
- ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM)European Heart Journal, 2008
- A propensity-matched study of the association of low serum potassium levels and mortality in chronic heart failureEuropean Heart Journal, 2007
- Appropriateness of Spironolactone Prescribing in Heart Failure Patients: A Population-Based StudyJournal of Cardiac Failure, 2006
- Adoption of Spironolactone Therapy for Older Patients With Heart Failure and Left Ventricular Systolic Dysfunction in the United States, 1998–2001Circulation, 2005
- The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart FailureNew England Journal of Medicine, 1999